NANP

N-acylneuraminate-9-phosphatase · Q8TBE9 · NANP on Sugi Atlas →

1,922 patent compounds predicted against NANP, 1,073 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL14669284	1.00	3/20
Sialic Acid (SCHEMBL3156058)	0.77	3/20
SCHEMBL2742889	0.74	3/20
SCHEMBL7066109	0.74	3/20
SCHEMBL8489507	0.74	3/20
SCHEMBL11936571	0.74	3/20
SCHEMBL12108940	0.74	3/20
SCHEMBL12108941	0.74	3/20
SCHEMBL13125452	0.74	3/20
SCHEMBL15976325	0.74	3/20
SCHEMBL17029902	0.74	3/20
SCHEMBL987055	0.73	3/20
SCHEMBL13191000	0.73	3/20
Sialic Acid (SCHEMBL22412)	0.72	3/20
Sialic Acid (SCHEMBL79085)	0.72	3/20
Sialic Acid (SCHEMBL236448)	0.72	3/20
Sialic Acid (SCHEMBL804644)	0.72	3/20
Sialic Acid (SCHEMBL2017776)	0.72	3/20
Sialic Acid (SCHEMBL2619258)	0.72	3/20
Sialic Acid (SCHEMBL8503823)	0.72	3/20

Clinical trials — most relevant to NANP by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Acelarin First Line Randomised Pancreatic Study	PHASE2/PHASE3	SUSPENDED
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer	PHASE1/PHASE2	COMPLETED
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)	PHASE1/PHASE2	RECRUITING
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases	PHASE1	COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides	PHASE1	COMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML)	nan	WITHDRAWN
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism	nan	NOT_YET_RECRUITING
Sialic Acid Supplementation in N-Acetylneuraminic Acid Synthase (NANS) Deficiency	nan	COMPLETED
Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB	nan	COMPLETED
Circulating miRNAs and Bone Microstructure in Adults With Hypophosphatasia	nan	UNKNOWN
Mucin Glycosylating Enzymes in Head and Neck Cancers	nan	UNKNOWN
Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)	nan	COMPLETED
The Natural History of Sialidosis Type I	nan	RECRUITING
Registry Gangliosidoses	nan	UNKNOWN
Evaluation of Blood Protein O-GlcNAcylation Levels in Children	nan	RECRUITING
The Effect of Monoallelic Variants in the ALPL Gene on the Natural Course of Hypophosphatasia in Russia	nan	RECRUITING
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.	nan	COMPLETED
Genetic Studies of Lysosomal Storage Disorders	nan	ENROLLING_BY_INVITATION
Biomarker for Hypophosphatasia Disease (BioHypophos)	nan	WITHDRAWN
Investigate eNAMPT in Multiple Myeloma Biology and Establish Its Role in Disease Progression	nan	COMPLETED
The Natural History of Alpha-Mannosidosis	nan	COMPLETED
Developing a Management Approach for Patients With Late-Onset Pompe Disease	nan	ACTIVE_NOT_RECRUITING
Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) Patients	nan	NOT_YET_RECRUITING
Million Veteran Program Return of Actionable Results	nan	COMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)	nan	WITHDRAWN
Using Next-generation Sequencing in the Diagnosis of Epilepsy and/or Intellectual Disability in a Pediatric Cohorte	nan	COMPLETED
Chromosome 9 P Minus Syndrome	nan	RECRUITING
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a NANP binder may also engage these)

Protein	Name	Similarity
Q5M969	—	1.000	Q5M969 →
Q9CPT3	—	1.000	Q9CPT3 →
Q5HZL9	—	0.985	Q5HZL9 →
Q9CYW4	—	0.983	Q9CYW4 →
Q08623	—	0.983	Q08623 →
Q7T012	—	0.982	Q7T012 →
Q9D5U5	—	0.981	Q9D5U5 →
Q12486	—	0.979	Q12486 →
Q6GLL2	—	0.978	Q6GLL2 →
B3DLB3	—	0.978	B3DLB3 →
Q0V9K2	—	0.978	Q0V9K2 →
Q95K79	—	0.977	Q95K79 →
Q96BT7	—	0.977	Q96BT7 →
D9IVE5	—	0.977	D9IVE5 →
Q8K370	—	0.977	Q8K370 →
Q9CWR2	—	0.976	Q9CWR2 →
Q9DBL7	—	0.976	Q9DBL7 →
Q6AYJ1	—	0.976	Q6AYJ1 →
EPHX2	Bifunctional epoxide hydrolase 2	0.976	landscape →
Q5ZKL5	—	0.975	Q5ZKL5 →
Q8MIR4	—	0.975	Q8MIR4 →
Q7SY73	—	0.975	Q7SY73 →
Q9GZT8	—	0.975	Q9GZT8 →
Q3UZW7	—	0.975	Q3UZW7 →
COASY	Bifunctional coenzyme A synthase	0.975	landscape →
Q80Y20	—	0.975	Q80Y20 →
Q58H57	—	0.975	Q58H57 →
Q8NBF2	—	0.975	Q8NBF2 →
PRMT9	Protein arginine N-methyltransferase 9	0.975	landscape →
Q32N48	—	0.974	Q32N48 →